The CVS Health Corporation (CVS) is Ronna Sue Cohen’s 3rd Largest Position

The CVS Health Corporation (CVS) is Ronna Sue Cohen’s 3rd Largest Position

Ronna Sue Cohen cut its position in shares of CVS Health Corporation (NYSE:CVS) by 0.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,642 shares of the pharmacy operator’s stock after selling 476 shares during the period. CVS Health Corporation accounts for approximately 3.4% of Ronna Sue Cohen’s investment portfolio, making the stock its 3rd largest position. Ronna Sue Cohen’s holdings in CVS Health Corporation were worth $4,596,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Acrospire Investment Management LLC boosted its position in shares of CVS Health Corporation by 542.2% in the second quarter. Acrospire Investment Management LLC now owns 1,066 shares of the pharmacy operator’s stock worth $102,000 after buying an additional 900 shares during the last quarter. Springbok Capital Management LLC boosted its position in shares of CVS Health Corporation by 190.5% in the first quarter. Springbok Capital Management LLC now owns 1,130 shares of the pharmacy operator’s stock worth $117,000 after buying an additional 741 shares during the last quarter. Pinkerton Retirement Specialists LLC boosted its position in shares of CVS Health Corporation by 3,475.0% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,144 shares of the pharmacy operator’s stock worth $110,000 after buying an additional 1,112 shares during the last quarter. MU Investments Co. Ltd. boosted its position in shares of CVS Health Corporation by 62.0% in the second quarter. MU Investments Co. Ltd. now owns 1,150 shares of the pharmacy operator’s stock worth $109,000 after buying an additional 440 shares during the last quarter. Finally, D Orazio & Associates Inc. boosted its position in shares of CVS Health Corporation by 9.4% in the second quarter. D Orazio & Associates Inc. now owns 1,160 shares of the pharmacy operator’s stock worth $111,000 after buying an additional 100 shares during the last quarter. 81.78% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CVS Health Corporation (NYSE:CVS) traded up 0.53% during midday trading on Friday, reaching $74.06. 3,529,190 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $81.80 and a 200-day moving average of $91.85. The stock has a market cap of $78.98 billion, a price-to-earnings ratio of 15.87 and a beta of 0.88. CVS Health Corporation has a one year low of $69.30 and a one year high of $106.67.

CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings results on Tuesday, November 8th. The pharmacy operator reported $1.64 EPS for the quarter, beating the Zacks’ consensus estimate of $1.57 by $0.07. CVS Health Corporation had a net margin of 2.96% and a return on equity of 17.18%. The firm had revenue of $44.60 billion for the quarter, compared to analysts’ expectations of $45.29 billion. During the same quarter in the prior year, the company posted $1.28 earnings per share. The business’s revenue for the quarter was up 15.5% on a year-over-year basis. On average, equities research analysts anticipate that CVS Health Corporation will post $5.81 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, November 3rd. Stockholders of record on Monday, October 24th were issued a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a dividend yield of 2.30%. The ex-dividend date of this dividend was Thursday, October 20th. CVS Health Corporation’s payout ratio is 36.40%.

Several brokerages recently issued reports on CVS. Mizuho reaffirmed a “buy” rating and set a $111.00 target price on shares of CVS Health Corporation in a research report on Friday, September 30th. Morgan Stanley reaffirmed a “hold” rating and set a $104.00 target price on shares of CVS Health Corporation in a research report on Monday, September 12th. Leerink Swann reaffirmed an “outperform” rating and set a $105.00 target price (down from $110.00) on shares of CVS Health Corporation in a research report on Sunday, October 2nd. Vetr lowered CVS Health Corporation from a “strong-buy” rating to a “hold” rating and set a $87.73 target price for the company. in a research report on Thursday, October 6th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating and set a $115.00 target price on shares of CVS Health Corporation in a research report on Tuesday, September 20th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $106.24.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

Related posts

Leave a Comment